Switch theme
Sign up to access all valuation multiples
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
2014
1.1K+
LTM Revenue $185M
LTM EBITDA $40.2M
$270M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ourofino has a last 12-month revenue (LTM) of $185M and a last 12-month EBITDA of $40.2M.
In the most recent fiscal year, Ourofino achieved revenue of $180M and an EBITDA of $43.3M.
Ourofino expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ourofino valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $185M | XXX | $180M | XXX | XXX | XXX |
| Gross Profit | $185M | XXX | $91.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $40.2M | XXX | $43.3M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $32.3M | XXX | $33.9M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $22.8M | XXX | $23.6M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $22.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ourofino's stock price is BRL 25 (or $4).
Ourofino has current market cap of BRL 1.3B (or $232M), and EV of BRL 1.5B (or $270M).
See Ourofino trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $270M | $232M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ourofino has market cap of $232M and EV of $270M.
Ourofino's trades at 1.5x EV/Revenue multiple, and 6.2x EV/EBITDA.
Equity research analysts estimate Ourofino's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ourofino has a P/E ratio of 10.2x.
See valuation multiples for Ourofino and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $232M | XXX | $232M | XXX | XXX | XXX |
| EV (current) | $270M | XXX | $270M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBIT | 8.4x | XXX | 8.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.2x | XXX | 9.8x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 52.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOurofino's last 12 month revenue growth is 6%
Ourofino's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Ourofino's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ourofino's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ourofino and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ourofino acquired XXX companies to date.
Last acquisition by Ourofino was XXXXXXXX, XXXXX XXXXX XXXXXX . Ourofino acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ourofino founded? | Ourofino was founded in 2014. |
| Where is Ourofino headquartered? | Ourofino is headquartered in Brazil. |
| How many employees does Ourofino have? | As of today, Ourofino has 1.1K+ employees. |
| Is Ourofino publicy listed? | Yes, Ourofino is a public company listed on BVMF. |
| What is the stock symbol of Ourofino? | Ourofino trades under OFSA3 ticker. |
| When did Ourofino go public? | Ourofino went public in 2014. |
| Who are competitors of Ourofino? | Similar companies to Ourofino include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ourofino? | Ourofino's current market cap is $232M |
| What is the current revenue of Ourofino? | Ourofino's last 12 months revenue is $185M. |
| What is the current revenue growth of Ourofino? | Ourofino revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Ourofino? | Current revenue multiple of Ourofino is 1.5x. |
| Is Ourofino profitable? | Yes, Ourofino is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ourofino? | Ourofino's last 12 months EBITDA is $40.2M. |
| What is Ourofino's EBITDA margin? | Ourofino's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Ourofino? | Current EBITDA multiple of Ourofino is 6.7x. |
| What is the current FCF of Ourofino? | Ourofino's last 12 months FCF is $15.9M. |
| What is Ourofino's FCF margin? | Ourofino's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Ourofino? | Current FCF multiple of Ourofino is 16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
